Concepts (139)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fontan Procedure | 11 | 2025 | 182 | 4.020 |
Why?
|
| Heart Defects, Congenital | 19 | 2025 | 1875 | 3.770 |
Why?
|
| Heart-Assist Devices | 7 | 2024 | 992 | 2.010 |
Why?
|
| Heart Transplantation | 7 | 2025 | 824 | 1.770 |
Why?
|
| Heart Failure | 6 | 2025 | 2314 | 1.370 |
Why?
|
| Cardiac Catheterization | 2 | 2020 | 623 | 0.920 |
Why?
|
| Liver Diseases | 4 | 2023 | 379 | 0.760 |
Why?
|
| Echocardiography | 4 | 2025 | 1125 | 0.710 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2020 | 18 | 0.640 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2025 | 1152 | 0.630 |
Why?
|
| Cardiac Rehabilitation | 1 | 2020 | 29 | 0.620 |
Why?
|
| Biological Products | 1 | 2021 | 141 | 0.610 |
Why?
|
| Aorta | 2 | 2020 | 520 | 0.600 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 437 | 0.600 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2020 | 160 | 0.590 |
Why?
|
| Heterotaxy Syndrome | 1 | 2019 | 63 | 0.590 |
Why?
|
| Down Syndrome | 2 | 2020 | 234 | 0.570 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 25 | 0.570 |
Why?
|
| Tricuspid Atresia | 1 | 2018 | 13 | 0.560 |
Why?
|
| Exercise Therapy | 1 | 2020 | 169 | 0.560 |
Why?
|
| Specialization | 1 | 2019 | 75 | 0.560 |
Why?
|
| Diagnostic Imaging | 1 | 2020 | 303 | 0.540 |
Why?
|
| Arterial Switch Operation | 1 | 2018 | 23 | 0.540 |
Why?
|
| Shock | 1 | 2019 | 94 | 0.540 |
Why?
|
| Turner Syndrome | 1 | 2018 | 44 | 0.530 |
Why?
|
| Survivors | 1 | 2019 | 346 | 0.510 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2020 | 267 | 0.510 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 172 | 0.500 |
Why?
|
| Creatinine | 1 | 2018 | 398 | 0.490 |
Why?
|
| Disease Management | 1 | 2020 | 559 | 0.490 |
Why?
|
| Palliative Care | 1 | 2020 | 443 | 0.480 |
Why?
|
| Renal Insufficiency | 1 | 2018 | 251 | 0.470 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 575 | 0.450 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 569 | 0.440 |
Why?
|
| Retrospective Studies | 14 | 2025 | 17614 | 0.420 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 551 | 0.410 |
Why?
|
| Adult | 15 | 2025 | 31127 | 0.410 |
Why?
|
| Cardiology | 1 | 2019 | 510 | 0.400 |
Why?
|
| Postoperative Complications | 3 | 2023 | 3112 | 0.390 |
Why?
|
| Tissue Engineering | 2 | 2011 | 153 | 0.380 |
Why?
|
| Polyurethanes | 1 | 2011 | 11 | 0.350 |
Why?
|
| Humans | 28 | 2025 | 130422 | 0.340 |
Why?
|
| Polymers | 1 | 2011 | 105 | 0.320 |
Why?
|
| Liver Transplantation | 3 | 2023 | 1136 | 0.310 |
Why?
|
| Pyrroles | 1 | 2011 | 184 | 0.310 |
Why?
|
| Young Adult | 7 | 2025 | 9995 | 0.300 |
Why?
|
| Heart Ventricles | 3 | 2025 | 757 | 0.290 |
Why?
|
| Internship and Residency | 1 | 2019 | 1215 | 0.280 |
Why?
|
| Postoperative Period | 2 | 2020 | 330 | 0.270 |
Why?
|
| Nanoparticles | 1 | 2011 | 297 | 0.270 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12860 | 0.270 |
Why?
|
| Transposition of Great Vessels | 2 | 2020 | 124 | 0.270 |
Why?
|
| Adolescent | 9 | 2025 | 20754 | 0.240 |
Why?
|
| Atrial Function | 1 | 2025 | 16 | 0.230 |
Why?
|
| Hospitalization | 3 | 2024 | 1927 | 0.220 |
Why?
|
| Male | 11 | 2025 | 64527 | 0.220 |
Why?
|
| Time Factors | 3 | 2025 | 6190 | 0.210 |
Why?
|
| Hospital Mortality | 4 | 2025 | 1065 | 0.200 |
Why?
|
| Endocarditis | 1 | 2024 | 103 | 0.200 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2023 | 31 | 0.200 |
Why?
|
| Heart Atria | 1 | 2025 | 333 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 300 | 0.180 |
Why?
|
| Child | 7 | 2025 | 26165 | 0.180 |
Why?
|
| Middle Aged | 6 | 2025 | 28383 | 0.170 |
Why?
|
| Hemodynamics | 2 | 2023 | 802 | 0.170 |
Why?
|
| Cyanosis | 1 | 2021 | 41 | 0.170 |
Why?
|
| Models, Cardiovascular | 1 | 2021 | 165 | 0.160 |
Why?
|
| Treatment Failure | 1 | 2021 | 351 | 0.160 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2020 | 8 | 0.160 |
Why?
|
| Female | 9 | 2025 | 70285 | 0.160 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2021 | 69 | 0.160 |
Why?
|
| Biocompatible Materials | 2 | 2011 | 108 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2020 | 119 | 0.150 |
Why?
|
| Hydrodynamics | 1 | 2019 | 28 | 0.150 |
Why?
|
| Patients | 1 | 2020 | 122 | 0.150 |
Why?
|
| Risk Factors | 4 | 2025 | 10942 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2021 | 520 | 0.140 |
Why?
|
| Swine | 1 | 2021 | 1184 | 0.140 |
Why?
|
| Comorbidity | 2 | 2021 | 1587 | 0.140 |
Why?
|
| Heart Valves | 1 | 2018 | 52 | 0.140 |
Why?
|
| Health Status | 1 | 2019 | 367 | 0.130 |
Why?
|
| Cause of Death | 1 | 2019 | 503 | 0.130 |
Why?
|
| Hypertension, Pulmonary | 1 | 2021 | 449 | 0.120 |
Why?
|
| Communication | 1 | 2020 | 531 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2018 | 372 | 0.120 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 5186 | 0.110 |
Why?
|
| Child, Preschool | 3 | 2025 | 14985 | 0.110 |
Why?
|
| Materials Testing | 2 | 2011 | 73 | 0.110 |
Why?
|
| Texas | 2 | 2020 | 3626 | 0.110 |
Why?
|
| Stents | 1 | 2020 | 780 | 0.100 |
Why?
|
| Curriculum | 1 | 2019 | 784 | 0.100 |
Why?
|
| Disease Progression | 1 | 2019 | 2205 | 0.100 |
Why?
|
| Age Factors | 1 | 2019 | 2835 | 0.100 |
Why?
|
| Electrochemical Techniques | 1 | 2011 | 8 | 0.090 |
Why?
|
| Electric Conductivity | 1 | 2011 | 80 | 0.090 |
Why?
|
| Myoblasts | 1 | 2011 | 34 | 0.090 |
Why?
|
| Ear Cartilage | 1 | 2010 | 2 | 0.080 |
Why?
|
| Incidence | 1 | 2018 | 3330 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2025 | 3803 | 0.080 |
Why?
|
| United States | 3 | 2024 | 11827 | 0.080 |
Why?
|
| Keratins | 1 | 2009 | 49 | 0.080 |
Why?
|
| Hair | 1 | 2009 | 30 | 0.080 |
Why?
|
| Prostheses and Implants | 1 | 2010 | 147 | 0.070 |
Why?
|
| Hemostatics | 1 | 2009 | 58 | 0.070 |
Why?
|
| Animals | 4 | 2021 | 33892 | 0.070 |
Why?
|
| Cell Line | 1 | 2011 | 2579 | 0.060 |
Why?
|
| Infant | 2 | 2020 | 13269 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8493 | 0.060 |
Why?
|
| Diastole | 1 | 2025 | 178 | 0.050 |
Why?
|
| Cardiac Output | 1 | 2023 | 152 | 0.050 |
Why?
|
| Cysts | 1 | 2023 | 88 | 0.050 |
Why?
|
| Diuretics | 1 | 2023 | 157 | 0.050 |
Why?
|
| Morbidity | 1 | 2023 | 259 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 66 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 90 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 111 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2021 | 78 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2021 | 116 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 20894 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 2131 | 0.040 |
Why?
|
| Mortality | 1 | 2021 | 258 | 0.040 |
Why?
|
| Rabbits | 2 | 2010 | 574 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 4656 | 0.040 |
Why?
|
| Kidney | 1 | 2023 | 1283 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3682 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 626 | 0.030 |
Why?
|
| Liver | 1 | 2023 | 1797 | 0.030 |
Why?
|
| Mice | 1 | 2011 | 18188 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2023 | 5069 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2023 | 6423 | 0.020 |
Why?
|
| Chondrocytes | 1 | 2010 | 49 | 0.020 |
Why?
|
| Thrombin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Hydrogels | 1 | 2010 | 91 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 166 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2009 | 256 | 0.020 |
Why?
|
| Amino Acids | 1 | 2009 | 562 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 574 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2009 | 974 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2009 | 1337 | 0.010 |
Why?
|